Quotables
"What, sir, would you make a ship sail against the wind and currents by lighting a bonfire under her deck? I pray you, excuse me, I have not the time to listen to such nonsense."
Napoleon Bonaparte ; When told of the Robert Fulton steamboat
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7335642 | Method for treating a viral infection related or a chemical toxin related hepatic injury with deltorphin D A method of modulating cytokine mediated hepatic injury by administering compound-D SEQ ID NO:1 to a mammal. A concentration of the compound in the range of about 0.5 mg/kg to about 20 mg/kg in a physiologically acceptable formulation blocks a cytokine cascade. A th... | 02/26/2008 |
| 7196059 | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith Pharmaceutical compositions that include insulin, an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component or a bile salt component without a fatty acid component are described. The insulin drug is covalently coupled to an oligomeric moi... | 03/27/2007 |
| 7169889 | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin The present invention relates generally to hydrolyzable drug-oligomer conjugates, pharmaceutical compositions comprising such conjugates, and to methods for making and using such conjugates and pharmaceutical compositions. For example, a conjugate of insulin, PEG, a... | 01/30/2007 |
| 7164021 | Opiate analogs selective for the δ-opioid receptor Novel compounds which selectively bind to the δ-opioid receptor have been designed. These compounds have greater selectivity, improved water (blood) solubility, and enhanced therapeutic value as analgesics. Because agonists with selectivity for the δ-opioid recept... | 01/16/2007 |
| 7118737 | Polymer-modified synthetic proteins The present invention relates to methods and compositions for modifying peptides, polypeptides and proteins with polymers, especially glyco-mimetic polymers, so as to improve their biological activity or pharmacokinetic properties. The invention further provides met... | 10/10/2006 |
| 7084121 | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same A mixture of conjugates in which each conjugate in the mixture comprises a calcitonin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may lower serum calcium levels in a subject by 10, 15 or even 20 percent or more. M... | 08/01/2006 |
| 7084114 | Mixtures of insulin drug-oligomer comprising polyalkylene glycol A mixture of conjugates in which each conjugate in the mixture comprises an insulin drug coupled to an oligomer that includes a polyalkylene glycol moiety is disclosed. The mixture may exhibit higher in vivo activity than a polydispersed mixture of similar conjugate... | 08/01/2006 |
| 7056713 | Urate oxidase The present invention relates, in general, to urate oxidase (uricase) proteins and nucleic acid molecules encoding same. In particular, the invention relates to uricase proteins which are particularly useful as, for example, intermediates for making improved modifie... | 06/06/2006 |
| 7030084 | Drug-oligomer conjugates with polyethylene glycol components The present invention relates generally to hydrolyzable drug-oligomer conjugates, pharmaceutical compositions comprising such conjugates, and to methods for making and using such conjugates and pharmaceutical compositions. For example, a conjugate of insulin, PEG, a... | 04/18/2006 |
| 6962818 | Mass defect labeling for the determination of oligomer sequences Mass tagging methods are provided that lead to mass spectrometer detection sensitivities and molecular discriminations that are improved over other methods. In particular the methods are useful for discriminating tagged molecules and fragments of molecules from chem... | 11/08/2005 |
| 6943148 | Methods for delivering therapeutics across blood-barrier and for altering receptor binding affinity The present invention relates to amphiphilic drug-oligomer conjugates capable of traversing the blood-brain barrier (“BBB”) and to methods of making and using such conjugates. An amphiphilic drug-oligomer conjugates comprise a therapeutic compound conjugated to ... | 09/13/2005 |
| 6908617 | Glycosylated modified primate lentivirus envelope polypeptides A modified polypeptide corresponding to an envelope glycoprotein of a primate lentivirus is described. The polypeptide has been modified from the wild-type structure so that it has at least two of the glycosylation sites proximal to the CD4 binding site or chemokine... | 06/21/2005 |
| 6875742 | Method for treating cytokine mediated hepatic injury A method of modulating cytokine mediated hepatic injury by administering compound-D SEQ ID NO:1 to a mammal. A concentration of the compound in the range of about 0.5 mg/kg to about 20 mg/kg in a physiologically acceptable formulation blocks a cytokine cascade. A th... | 04/05/2005 |
| 6852834 | Fusion peptides isolatable by phase transition Genetically-encodable, environmentally-responsive fusion proteins comprising ELP peptides. Such fusion proteins exhibit unique physico-chemical and functional properties that can be modulated as a function of solution environment. The invention also provides methods... | 02/08/2005 |
| 6740639 | Inclusion complees of a high potent opioid peptide, pharmaceutical compositions and method of treatment The invention provides novel inclusion complexes of highly potent opioid peptide of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with cyclodextrin, pharmaceutical preparations containing these inclusion complexes of L-Tyrosyl-D-alanyl-glycyl-... | 05/25/2004 |
| 6737397 | Control of cancer growth through the interaction of [MET5]-enkephalin and the zeta receptor The present invention is related to the treatment and prevention of cancer including particularly gastrointestinal cancer. More specifically, the present invention describes the use of naltrexone, naloxone and the pentapeptide growth factor [Met5]-enkepha... | 05/18/2004 |
| 6673769 | Lanthionine bridged peptides Disclosed are lanthionine bridged peptides having the structure ##STR1## methods of their preparation and their use as pharmacologically active agents.... | 01/06/2004 |
| 6596778 | ଲ-endorphin peptides for treating muscle-wasting diseases An active ଲ-endorphin fragment or an analog of such a fragment is provided to a patient for alleviating the effect of muscle-wasting disease and for inhibiting or reducing leakage of an enzyme from a living muscle. The ଲ-endorphin fragment is ... | 07/22/2003 |
| 6506730 | Nasal transmucosal delivery of peptide conjugated with biocompatible polymers The present invention relates to a pharmaceutical composition for the nasal transmucosal delivery of a biocompatible polymer-biologically active peptide conjugate. The pharmaceutical composition of the present invention increases the water solubility of p... | 01/14/2003 |
| 6380164 | Method for treating cytokine mediated hepatic injury A method of modulating cytokine mediated hepatic injury by administering deltorphins to a mammal. Deltorphin I SEQ ID NO:1, deltorphin II SEQ ID NO:2 or combinations of deltorphins I SEQ ID NO:1 and II SEQ ID NO:2 may be administered. A deltorphin concent... | 04/30/2002 |
| 6359111 | Opioid receptor targeting A compound comprising a ligand portion which has binding affinity for an opioid receptor, and a therapeutically or diagnostically effective group selected from radionuclide chelating agents, fluorochromes, toxins, drugs, polyboron moieties, proteins, biol... | 03/19/2002 |
| 6337319 | μ-Selective opioid peptides This invention relates to novel opioid peptides for the treatment of pain as well as a method for the preparation thereof and pharmaceutically acceptable compositions comprising these peptides. The invention also relates to methods for controlling pain in... | 01/08/2002 |
| 6303578 | Mu-opiate receptor peptides This invention relates to certain peptides and linear and cyclic analogs thereof that bind to the mu (morphine) opiate receptor with higher affinity, selectivity and potency than currently available peptides. This invention also relates to pharmaceutical ... | 10/16/2001 |
| 6268339 | Lanthionine bridged peptides Disclosed are lanthionine bridged peptides having the structure ##STR1## methods of their preparation and their use as pharmacologically active agents.... | 07/31/2001 |
| 6251625 | Process for preparing peptides and N-carbamoyl-protected peptides The invention concerns a process for the enzymatic preparation of protected di- and oligopeptides and the separation of the protective groups used. The process according to the invention enables peptides to be synthesized simply and economically and the p... | 06/26/2001 |
| 6136780 | Control of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (.zeta.) receptor The present invention is related to the treatment and prevention of cancer including particularly gastrointestinal cancer. More specifically, the present invention describes the use of naltrexone, naloxone and the pentapeptide growth factor [Met5 | 10/24/2000 |
| 6054557 | Fluorescent peptides The invention provides biologically active compounds of the formula: ##STR1## where R1 is a light-emitting moiety and R7 is a peptide of between 2 and 200 amino acids. X is selected from the group including .dbd.O, .dbd.S, --OH,... | 04/25/2000 |
| 6028168 | Lanthionine bridged peptides Disclosed are lanthionine peptides having the structure ##STR1## methods of their preparation and use as pharmacologically active agents.... | 02/22/2000 |
| 5776903 | Peptide derivatives usable as zinc endopeptidase 24-15 inhibitors Peptide derivatives usable as zinc endopeptidase 24-15 inhibitors. These peptide derivatives have the following amino acid sequence: -Phe.psi.(PO2 CH2)-.sub.(L,D) Xaa'-Yaa'-Zaa'- in which .psi.(PO2 CH2) indicates that the pept... | 07/07/1998 |
| 5747261 | Protein related to but distinct from EGF receptor and antibodies reactive therewith The isolation, cloning and characterization of a human gene related to but distinct from EGF receptor gene has been described. Nucleotide sequence of the gene and amino acid sequence of the polypeptide encoded by the gene have been determined. The use of ... | 05/05/1998 |
| 5733881 | Opioid peptide antagonists Compounds of the formula I as well as methods for their preparation, their pharmaceutical preparations and their use. ##STR1## The compounds of formula I are useful in therapy, especially as analgesics and as immunosuppresive agents.... | 03/31/1998 |
| 5652335 | Physiologically active substance well capable of permeating biomembrane A physiologically active substance well capable of permeating biomembrane according to the present invention is represented by: ##STR1## where R represents a residue of a physiologically active substance comprising a peptide, amino acid, aliphatic am... | 07/29/1997 |
| 5627268 | Hemoglobin comprising globin fusion proteins The present invention relates to a novel method for making a predetermined, desired peptide in transgenic animals and can be advantageously used for the production of large quantities of the desired peptide. More particularly, the invention concerns the e... | 05/06/1997 |
| 5558987 | Blood levels of CCK peptides relative to panic disorder treatment A method of treating a patient having a panic disorder, the patient having an elevated CCK peptide plasma level, by lowering the plasma CCK peptide level of the patient. A further method provides a diagnosis of panic disorder in a patient by detecting if ... | 09/24/1996 |
| 5428128 | Site specific synthesis of conjugated peptides Processes for synthesizing polypeptides containing substantially non-antigenic polymers, preferably poly(alkylene glycols) in specifically predetermined sites are disclosed. Polypeptides prepared by such processes acre also disclosed.... | 06/27/1995 |
| 5276137 | Analgesic peptides with a trifluoronorvaline modification The present invention relates to analgesic enkephalin derivatives represented by the following formula: Tyr-A1 -A2 -A3 -A4 SEQ ID NO:5 (1) and the acid salts thereof, wherein Tyr is L-tyrosine, A1 or A | 01/04/1994 |
| 5169833 | Substituted cyclic pentapeptides The present invention provides substituted cyclic pentapeptide compounds of general Formula I: ##STR1## and the pharmaceutically-acceptable slats, esters and amides thereof, which are useful for inducing analgesia in animals, pharmaceutical comp... | 12/08/1992 |
| 5154924 | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates The present invention pertains to a method for delivering a neuropharmaceutical agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of an antibody-neuropharmaceutic... | 10/13/1992 |
| 5061691 | Enkephalin analogs The invention relates to enkephalin analogs of the formula ##STR1## wherein in case of X is D-Val, D-Phe, Pro, D-Met, D-Met(O), D-Leu, D-Glu, D-Glu(Obzl), D-Lys, D-Lys(Z), or D-Arg, Y is Gly or Phe; and R is a) a direct bond, b) an alkylene group having f... | 10/29/1991 |
| 5017689 | Dynorphin analogs specific for kappa opioid receptors Cyclic disulfide and linear dynorphin Dyn A1-11 and dynorphin Dyn A1-13 analogs which are highly specific for .kappa. opioid receptors. These analogs are useful in pharmaceutical compositions and for the analysis of opioid receptor/l... | 05/21/1991 |
